Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.27 +0.39 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Hopeful Golden Cross Forms On Sanofi's Chart
Via Benzinga
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
It's difficult to imagine a future where healthcare isn't in high demand. 
Via The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
The Viral “Tripledemic” Opportunity
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu... 
Via Talk Markets
What Does Sanofi's Debt Look Like?
Over the past three months, shares of Sanofi Inc. (NASDAQ:SNY) increased by 20.92%. Before having a look at the importance of debt, let's look at how much debt Sanofi has. 
Via Benzinga
Sanofi Forecasts Foreign Exchange, Record Flu Vaccine Sales To Boost Q4 Earnings
Via Benzinga
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Via Benzinga
What This Drug News Could Mean for Sanofi Shareholders
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease. 
Via The Motley Fool
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
FDA Permits Pharmacies To Distribute Abortion Pills, Tesla's Aggressive Discounting May Have Hit Gross Margins, Goldman Sachs Bullish On M&A Activity In Late 2023: Top Stories Today
Reuters Goldman Sachs Bullish On M&A Deals Activity Picking Up In Late 2023 
Via Benzinga
Could This Drug News Give a Lift to Eli Lilly Stock?
In November, Eli Lilly received positive news from the U.S. Food and Drug Administration. 
Via The Motley Fool
3 Medical Dividend Stocks That Hit the Sweet Spot
These three offer high dividend yields and consistent revenue growth. 
Via The Motley Fool
After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
Via Benzinga
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
2 Best Biotech Stocks to Buy Right Now
Demand for medicines and vaccines has nowhere to go but up over the long run. 
Via The Motley Fool
Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis
Via Benzinga
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase. 
Via InvestorPlace
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Via Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
The company is working on protein degradation in cancer and inflammatory diseases. 
Via Investor's Business Daily
Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal
HZNP stock is up on news that Horizon Therapeutics is being bought by Amgen in a friendly deal that's positive for both companies. 
Via InvestorPlace
Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal
The deal comes a day after Sanofi dropped out of the bidding process. 
Via Investor's Business Daily
Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12
Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU 
Via Benzinga
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
Via Benzinga
Will This Potential Approval Be a Winner for Sanofi's Shareholders?
Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union. 
Via The Motley Fool
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.